• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Current researches and progresses on new antibody drugs in the treatment of relapsed/refractory diffuse large B-cell lymphoma].[新型抗体药物治疗复发/难治性弥漫性大B细胞淋巴瘤的研究现状与进展]
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):259-264. doi: 10.3760/cma.j.issn.0253-2727.2023.03.016.
2
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
3
Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.利妥昔单抗：在慢性淋巴细胞白血病、低级别或滤泡性淋巴瘤以及弥漫性大 B 细胞淋巴瘤中的应用综述。
Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000.
4
Relapsed large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.复发性大B细胞非霍奇金淋巴瘤：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2007 Apr;18 Suppl 2:ii57-8. doi: 10.1093/annonc/mdm038.
5
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.复发/难治性伴有MYC易位的弥漫性大B细胞淋巴瘤采用泊洛妥珠单抗、苯达莫司汀和利妥昔单抗治疗的临床结局较差。
J Clin Exp Hematop. 2023 Sep 28;63(3):201-204. doi: 10.3960/jslrt.23017. Epub 2023 Jul 28.
6
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands.复发或难治性弥漫性大B细胞淋巴瘤患者的治疗与转归：荷兰一项当代全国性基于人群的研究
Blood Cancer J. 2024 Jan 4;14(1):3. doi: 10.1038/s41408-023-00970-z.
7
More than a lonca-shot: beating the odds in relapsed/ refractory diffuse large B-cell lymphoma.不止一线生机：在复发/难治性弥漫性大B细胞淋巴瘤中战胜困难
Haematologica. 2024 Apr 1;109(4):1022-1024. doi: 10.3324/haematol.2023.284056.
8
Cytomegalovirus-induced stomatitis in a patient with refractory diffuse large B-cell lymphoma.一名难治性弥漫性大B细胞淋巴瘤患者的巨细胞病毒诱导性口腔炎
Int J Hematol. 2023 May;117(5):629-630. doi: 10.1007/s12185-023-03593-z. Epub 2023 Apr 3.
9
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.来那度胺治疗 B 细胞非霍奇金淋巴瘤的全面综述。
Ann Oncol. 2015 Aug;26(8):1667-77. doi: 10.1093/annonc/mdv102. Epub 2015 Feb 23.
10
Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma.奥雷巴替尼和来那度胺联合R-mini CDOP方案治疗复发/难治性侵袭性B细胞非霍奇金淋巴瘤的疗效和安全性
Turk J Haematol. 2023 Dec 5;40(4):284-285. doi: 10.4274/tjh.galenos.2023.2023.0263. Epub 2023 Sep 1.

本文引用的文献

1
Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019.中国淋巴瘤负担，1990-2019 年：基于 2019 年全球疾病、伤害和危险因素研究的分析。
Aging (Albany NY). 2022 Apr 10;14(7):3175-3190. doi: 10.18632/aging.204006.
2
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.奥德罗内昔单抗，一种针对 CD20 阳性 B 细胞恶性肿瘤的人源 CD20×CD3 双特异性抗体（ELM-1）：在一项单臂、多中心、1 期临床试验中，复发或难治性非霍奇金淋巴瘤队列的结果。
Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1.
3
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.单药莫昔单抗在复发或难治性 B 细胞淋巴瘤患者中显示出持久的完全缓解：I 期剂量递增研究。
J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16.
4
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.复发或难治性弥漫性大 B 细胞淋巴瘤中 Brentuximab vedotin 与来那度胺联合应用的 1 期/剂量扩展试验。
Blood. 2022 Mar 31;139(13):1999-2010. doi: 10.1182/blood.2021011894.
5
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.波拉珠单抗维地布汀联合苯达莫司汀和利妥昔单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤：生存数据更新及新扩展队列数据。
Blood Adv. 2022 Jan 25;6(2):533-543. doi: 10.1182/bloodadvances.2021005794.
6
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.皮下注射依鲁替尼在复发或难治性 B 细胞非霍奇金淋巴瘤患者中的剂量递增：一项开放标签、1/2 期研究。
Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.
7
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.L-MIND 研究中 tafasitamab（MOR208）联合来那度胺治疗复发/难治性弥漫性大 B 细胞淋巴瘤患者的长期结果。
Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958.
8
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Loncastuximab tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤（LOTIS-2）：一项多中心、开放标签、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11.
9
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.戈利木单抗，一种新型、双价 CD20 靶向 T 细胞衔接双特异性抗体，在复发或难治性 B 细胞淋巴瘤中诱导持久完全缓解：一项 I 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
10
Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.在中国多中心真实世界研究中的难治性弥漫性大 B 细胞淋巴瘤的结果。
Cancer Commun (Lond). 2021 Mar;41(3):229-239. doi: 10.1002/cac2.12126. Epub 2021 Jan 22.

[Current researches and progresses on new antibody drugs in the treatment of relapsed/refractory diffuse large B-cell lymphoma].

作者信息

Xu P P, Zhao W L

机构信息

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Center for Translational Medicine (Shanghai), Hematology Department of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):259-264. doi: 10.3760/cma.j.issn.0253-2727.2023.03.016.

DOI:10.3760/cma.j.issn.0253-2727.2023.03.016
PMID:37356992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10119730/
Abstract
摘要